AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
Breaking barriers
to develop better antibody medicines for patients.
- Regeneron
- Lilly
- Moderna
- Gilead
- Novartis
- Abdera
- Denali
- Incyte
- IGM
- Teva
- Regeneron
- Lilly
- Moderna
- Gilead
- Novartis
- Abdera
- Denali
- Incyte
- IGM
- Teva
We are developing potential first-in-class and best-in-class antibody medicines.
We are focused on bringing innovative medicines to patients, both by advancing our internal pipeline of programs and partnering with companies that have novel science or innovative technology.
We have developed antibody discovery and development technologies to unlock high-value drug classes and targets, including T-cell engagers for cancer and transmembrane proteins for indications such as metabolic and endocrine conditions, pain, autoimmunity, and more.
People connected in purpose.
We are a team of scientists, engineers, creatives, and business professionals who believe that advancing science enhances lives.
And it all starts with our team. We’ve built a place where people feel they are part of something bigger than themselves. A place that exists to push the limits of science and technology, and aims to bring better therapies to patients.
Connect with us.
Meet with our team to discuss how we can expand the reach of antibody therapies.